CVS Health Corporation $CVS Holdings Decreased by Pzena Investment Management LLC

Pzena Investment Management LLC decreased its stake in shares of CVS Health Corporation (NYSE:CVS) by 5.4% during the third quarter, HoldingsChannel reports. The firm owned 15,844,972 shares of the pharmacy operator’s stock after selling 901,881 shares during the quarter. CVS Health makes up about 3.9% of Pzena Investment Management LLC’s investment portfolio, making the stock its 6th largest position. Pzena Investment Management LLC’s holdings in CVS Health were worth $1,194,552,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CVS. Stephens Inc. AR grew its position in shares of CVS Health by 12.0% during the 2nd quarter. Stephens Inc. AR now owns 30,620 shares of the pharmacy operator’s stock valued at $2,112,000 after acquiring an additional 3,285 shares during the period. Avidian Wealth Enterprises LLC boosted its stake in CVS Health by 100.2% during the 2nd quarter. Avidian Wealth Enterprises LLC now owns 6,071 shares of the pharmacy operator’s stock worth $419,000 after purchasing an additional 3,038 shares during the last quarter. Cullen Frost Bankers Inc. raised its holdings in CVS Health by 7.7% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 6,190 shares of the pharmacy operator’s stock valued at $427,000 after acquiring an additional 444 shares during the last quarter. D.A. Davidson & CO. increased its holdings in shares of CVS Health by 12.9% in the second quarter. D.A. Davidson & CO. now owns 204,761 shares of the pharmacy operator’s stock valued at $14,124,000 after purchasing an additional 23,403 shares during the last quarter. Finally, Citizens & Northern Corp increased its stake in shares of CVS Health by 2.9% in the 2nd quarter. Citizens & Northern Corp now owns 28,324 shares of the pharmacy operator’s stock worth $1,954,000 after acquiring an additional 804 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Down 0.5%

CVS opened at $77.81 on Thursday. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The firm has a market cap of $98.99 billion, a P/E ratio of 56.38, a P/E/G ratio of 0.82 and a beta of 0.50. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The business has a fifty day simple moving average of $78.65 and a 200-day simple moving average of $76.57.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.CVS Health’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the business posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is presently 192.75%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $101.00 target price (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Argus decreased their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Evercore raised their target price on CVS Health from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Finally, Robert W. Baird raised their price objective on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Nineteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.91.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.